Results
|
10921.
|
|
|
10922.
|
|
|
10923.
|
|
|
10924.
|
|
|
10925.
|
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. [electronic resource] by
- Müller, Dirk
- Fischer, Kirsten
- Kaiser, Peter
- Eichhorst, Barbara
- Walshe, Ronald
- Reiser, Marcel
- Kellermann, Lenka
- Borsi, Lisa
- Civello, Daniele
- Mensch, Alexander
- Bahlo, Jasmin
- Hallek, Michael
- Stock, Stephanie
- Fingerle-Rowson, Günter
Producer: 20170106
In:
Leukemia & lymphoma vol. 57
Availability: No items available.
|
|
10926.
|
|
|
10927.
|
|
|
10928.
|
|
|
10929.
|
|
|
10930.
|
|
|
10931.
|
|
|
10932.
|
In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. [electronic resource] by
- Robin, Philippe
- Kumar, Srishti
- Salaun, Pierre-Yves
- Le Roux, Pierre-Yves
- Couturaud, Francis
- Planquette, Benjamin
- Merah, Adel
- Roy, Pierre-Marie
- Thavorn, Kednapa
- Le Gal, Grégoire
Producer: 20190114
In:
Thrombosis research vol. 171
Availability: No items available.
|
|
10933.
|
|
|
10934.
|
|
|
10935.
|
|
|
10936.
|
|
|
10937.
|
|
|
10938.
|
|
|
10939.
|
|
|
10940.
|
|